343238-58-4

Usage

Uses

Used in Pharmaceutical Industry:
Azetidine-3-carboxylic acid methyl ester serves as a key building block in the synthesis of various pharmaceuticals due to its unique ring structure and reactivity, contributing to the development of new drugs for treating a range of diseases and conditions.
Used in Agrochemical Industry:
azetidine-3-carboxylic acid methyl ester is utilized as an intermediate in the production of agrochemicals, playing a crucial role in the synthesis of bioactive molecules that help protect crops from pests and diseases, thereby enhancing agricultural productivity.
Used in Organic Synthesis:
Azetidine-3-carboxylic acid methyl ester is employed as a versatile synthetic building block in organic chemistry for the preparation of a variety of organic compounds, showcasing its adaptability in creating complex molecular structures.
Used in Chemical and Biotechnology Research:
azetidine-3-carboxylic acid methyl ester is applied in research settings within the fields of chemistry and biotechnology, where it is explored for its potential to develop new materials and substances, further expanding its utility and impact on scientific advancements.

InChI:InChI=1/C5H9NO2/c1-8-5(7)4-2-6-3-4/h4,6H,2-3H2,1H3

Upstream product

• 67-56-1 methanol 
• 36476-78-5 3-azetidinecarboxylic acid 

Downstream Products

• 1150646-53-9 C₂₈H₃₈N₆O₅ 
• 1334608-13-7 methyl 1-{[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-5-pyrimidinyl)-2-ethylphenyl]methyl}-3-azetidinecarboxylate 
• 1344998-39-5 methyl 1-(3-bromo-2-ethylbenzyl)azetidine-3-carboxylate 
• 1344997-80-3 methyl 1-{2-[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl]ethyl}-3-azetidinecarboxylate 
• 610791-05-4 azetidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester 
• 1611442-82-0 1-((2-fluoro-4’-(spiro[3.5]nonan-7-yloxy)-[1,1‘-biphenyl]-3-yl)methyl)azetidine-3-carboxylic acid 
• 1444255-08-6 methyl 1-(4-(5-(4-isopropoxyphenyl)thiazol-2-yl)benzyl)azetidine-3-carboxylate 
• 1422129-06-3 methyl 1-[2,4-bis(trifluoromethyl)benzyl]azetidine-3-carboxylate 
• 1266115-94-9 methyl 1-((6-(trans-4-tert-butylcyclohexyloxy)-5-(trifluoromethyl)naphthalen-2-yl)methyl)azetidine-3-carboxylate 
• 1266119-18-9 methyl 1-(1-(6-((trans)-4-tert-butylcyclohexyloxy)quinolin-2-yl)ethyl)azetidine-3-carboxylate 
• 1344997-46-1 methyl 1-[2-(3-{5-[3-cyano-4-(2-methylpropyl)phenyl]-1,3,4-thiadiazol-2-yl}-2-ethylphenyl)ethyl]-3-azetidinecarboxylate 

Relevant academic research and scientific papers

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

Polysubstituted-indazole compounds and application of same as IDO inhibitors

The invention discloses polysubstituted-indazole compounds as shown in a formula (I) which is described in the specification, a preparation method for the compounds, and application of the compounds as IDO inhibitors. The compounds provided by the invention can be used for preventing and/or treating a plurality of diseases, such as Alzheimer's disease, cataract, infections related to cellular immune activation, autoimmune diseases, AIDS, cancers, depression, the metabolic disorder of tryptophan or the like.

2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors

Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hy

2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors

Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hy